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Introduction: Osteoporosis is a disease characterized by low bone mineral density and poor 
bone quality resulting in reduced bone strength and increased risk of fracture. Oral bisphos-
phonates, first-line therapy for most patients with osteoporosis, are associated with suboptimal 
adherence to therapy due to factors that include a complex dosing regimen and gastrointestinal 
intolerance in some patients. Intravenous bisphosphonates address these limitations through 
infrequent injectable dosing that assures 100% bioavailability. Intravenous zoledronic acid is 
the newest bisphosphonate to be approved for the treatment of osteoporosis.
Aims: This review assesses the evidence for the therapeutic effects of intravenous zoledronic 
acid for the treatment of osteoporosis.
Evidence review: Zoledronic acid 5 mg administered as an annual 15-min intravenous infusion 
has been shown to reduce the risk of vertebral fractures, hip fractures, and other fractures in a 
three-year randomized, double-blind, placebo-controlled trial in women with postmenopausal 
osteoporosis. In a randomized, double-blind, placebo-controlled trial in women and men with 
a recent surgical repair of low-trauma hip fracture, it reduced the risk of new clinical fractures 
and improved survival. In both studies, zoledronic acid was associated with a good safety profile 
and was generally well tolerated. Zoledronic acid has the potential to improve clinical outcomes 
by reducing the risk of fracture in patients with osteoporosis.
Clinical value: Intravenous zoledronic acid 5 mg every 12 months reduces fracture risk in women 
with postmenopausal osteoporosis and in women and men with recent low-trauma hip fracture.
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Core evidence clinical impact summary for once yearly intravenous zoledronic 
acid in the treatment of osteoporosis
Outcome measure Evidence Implications
Patient-oriented evidence
Fracture risk reduction Clear reduced risk of vertebral, hip, and nonvertebral 
fractures in women with postmenopausal 
osteoporosis and reduced risk of clinical fractures in 
men and women with recent low-trauma hip fracture
reduced mortality Moderate All-cause mortality rate may be decreased in patients 
treated after recent low-trauma hip fracture
Disease-oriented evidence
Bone density increase Clear increase in bone density at lumbar spine and hip
Bone turnover suppression Clear rapid suppression of bone turnover markers that is 
sustained for at least one year
Economic evidence
Cost-effectiveness 
 
Moderate 
 
Higher cost of zoledronic acid compared with generic 
oral bisphosphonate may, in part, be offset by assured 
therapeutic effect for at least one year after infusionCore Evidence 2009:4 14
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Scope, aims, and objectives
Zoledronic acid (zoledronate) 5 mg (Reclast® in the US, 
Aclasta® in other countries; Novartis Pharmaceutical 
Corporation, East Hanover, NJ, USA) is approved by the 
FDA as a once yearly treatment for osteoporosis in post-
menopausal women, diagnosed by bone mineral density 
(BMD) or prevalent vertebral fracture, and for treatment of 
patients (men and women) at high risk of fracture, defined as 
a recent low-trauma hip fracture. It is approved as a single-
dose treatment of Paget’s disease of bone in men and women. 
Zoledronic acid is also available as a 4 mg dose (Zometa®, 
Novartis Pharmaceutical Corporation, East Hanover, NJ, 
USA) that is FDA-approved for the treatment of hypercalce-
mia of malignancy, multiple myeloma, and bone metastases 
of solid tumors, given as often as every 3–4 weeks.
Zoledronic acid is an aminobisphosphonate with a high 
affinity for mineralized bone. Administered as an intravenous 
infusion over at least 15 min, it rapidly localizes to bone, 
where it inhibits osteoclastic bone resorption by inhibiting 
the action of the enzyme farnesyl pyrophosphate synthase 
in the mevalonate pathway. The relatively long duration of 
action of zoledronic acid is attributable to its high binding 
affinity for bone mineral.
This review addresses the evidence for the use of zole-
dronic acid in the treatment of osteoporosis in women and 
men. Zoledronic acid for the treatment of Paget’s disease of 
bone and cancer-related conditions is not considered here.
Methods
Evidence for the role of zoledronic acid in the treatment 
of osteoporosis was obtained through a literature search 
conducted on August 25, 2008, using the terms “zoledronic 
acid” and “osteoporosis” (search 1) or “fracture” (search 2) 
in the PubMed (http://www.ncbi.nlm.nih.gov/pubmed/) data-
base with limits of  “humans,” “clinical trials,” and “English.” 
Search 1 identified 26 matches and search 2 identified 
46 matches. A review of all matches eliminated duplicates, 
review articles, studies in patients with cancer-related 
conditions, and studies not having fractures as the primary 
endpoint. A search of the National Guideline Clearinghouse 
(http://www.guide.gov), the Cochrane Database of System-
atic Reviews (http://cochrane.org/index0. htm), and Evidence 
Based Medicine Reviews (http://www.acpjc. org) using the 
same search terms revealed no additional matches meeting 
study criteria. Two large phase III randomized, double-
blind, placebo-controlled clinical trials with fractures as a 
primary endpoint were found: Health Outcomes and Reduced 
Incidence with Zoledronic Acid Once Yearly (HORIZON) 
Pivotal Fracture Trial (PFT)1 and HORIZON Recurrent 
Fracture Trial (RFT).2 Each study provided level 2 evidence 
on the efficacy and safety of zoledronic acid for the treatment 
of osteoporosis. A third study of clinical relevance, also with 
level 2 evidence but not powered to assess differences in 
fracture risk, was evaluated.3 This was a randomized, double-
blind, double-dummy, multicenter trial assessing the safety 
and efficacy of a single dose of zoledronic acid 5 mg versus 
alendronate 70 mg/week in postmenopausal women previ-
ously treated with alendronate. These studies provided the 
focus of this evidence review, with other supporting studies 
presented when appropriate to enhance understanding of the 
use of zoledronic acid in the treatment of osteoporosis.
Table 1 summarizes the levels of evidence of articles 
identified from the search strategy.
Disease overview
Osteoporosis is a disease characterized by low BMD and 
poor bone quality that results in reduced skeletal strength 
and increased risk of fracture.4 It is diagnosed by measur-
ing a patient’s BMD by dual-energy x-ray absorptiometry 
(DXA) and applying criteria established by the World Health 
Organization (WHO).5 If a fragility fracture has occurred, a 
clinical diagnosis of osteoporosis may be made independently 
of BMD once other causes of skeletal fragility have been 
eliminated. There are no symptoms of osteoporosis until a 
fracture occurs.
Osteoporosis and low bone mass (osteopenia) are common 
conditions that affect about 44 million people in the US.6 
Worldwide, osteoporosis is estimated to be present in over 
200 million individuals.7 While osteoporosis can occur at 
Table1 Evidence base included in the review
Category Number of records
  Full papers Abstracts
initial search 72 0
  records excluded 70 0
  records included 2 0
Additional studies identified 1 0
Level 1 clinical evidence 0 0
Level 2 clinical evidence 3 0
Level  3 clinical evidence 0 0
  Trials other than rCT 0 0
  Case reports 0 0
Economic evidence 0 0
Notes: For definitions of levels of evidence see Core Evidence website (http://www.
dovepress.com/core-evidence-journal).
Abbreviation: rCT, randomized controlled trial.Core Evidence 2009:4 15
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any age, it becomes more common with aging, predisposing 
many older individuals to fractures.4 About 55% of adults 
aged 50 and older are at risk, 80% of whom are women.6 
An estimated 50% of women and 25% of men above age 
50 will sustain an osteoporotic fracture of the hip, spine, or 
wrist during the remainder of their lifetime.6 Fracture risk 
increases with decreasing BMD, advancing age, and in the 
presence of clinical risk factors that include previous fracture, 
parent with hip fracture, current cigarette smoking, chronic 
glucocorticoid use, rheumatoid arthritis, and excess alcohol 
intake.8 The burden of osteoporosis is expected to worsen 
in the future, in part due to the aging of the population. In 
2005 there were an estimated two million new osteoporotic 
fractures in the US; by 2025, that number is predicted to 
increase to three million.9
Osteoporotic fractures are associated with substantial 
morbidity and mortality. These fractures may cause acute and 
chronic pain, diminished quality of life, and high healthcare 
expenses for the individual and society. Nearly one-third of 
hip fracture patients enter a nursing home within a year of 
their fracture, and 20% of osteoporotic hip fracture patients 
die within that same time period.4 Loss of independence is a 
major fear of the elderly, with 80% of women above the age 
of 75 preferring death to placement in a nursing home as a 
result of a hip fracture.4 Fractures of the hip, spine, or wrist 
have been found to affect quality of life measures to a degree 
that is similar to that seen in other serious chronic diseases 
such as asthma, chronic obstructive pulmonary disease, and 
osteoarthritis.10
The total direct cost of osteoporosis-related medical care 
is estimated to be $US17 billion annually in the US9 and 
€31.7 billion in the EU.8 Hip fractures account for 14% of 
incident fractures and 72% of fracture costs, with the number 
of hip fractures and associated costs expected to double or 
triple by 2040.11 Following a fracture, a patient’s overall 
healthcare expenses increase as well. In a population-based 
study of patients from Olmsted County, Minnesota, US, 
the direct medical costs in the year following a fracture 
increased from $US761 to $US3884 per patient.12 Indirect 
costs due to lost wages and diminished productivity of 
the patient and/or caregiver were not considered in this 
analysis. It is likely that the true socioeconomic burden of 
osteoporotic fractures is greatly underestimated by most 
studies.4
In collaboration with numerous medical societies, the 
National Osteoporosis Foundation (NOF) developed and 
recently released an updated comprehensive clinicians’ guide 
for the management of osteoporosis.13 This guide is intended 
to be used by clinicians to assist in making decisions in the 
evaluation and treatment of individual patients. It provides 
indications for BMD testing in postmenopausal women and 
men aged 50 years and older, and suggests ways to evaluate 
patients for factors contributing to low BMD and skeletal 
fragility. NOF treatment recommendations are based on 
BMD and/or personal history of fracture, or an assessment 
of 10-year fracture probability according to a US adaptation 
of the WHO fracture risk algorithm, FRAX™.14 The NOF 
guide focuses on providing clinical tools for the identification 
of patients who are at high risk of fracture and most likely 
to benefit from pharmacologic intervention.
Current therapeutic options
Universal recommendations for skeletal health in all adults 
over age 50 include a daily intake of at least 1200 mg 
elemental calcium with diet, plus supplements, if needed, 
and vitamin D3 800–1000 IU.13 Regular weight-bearing 
exercise and muscle-strengthening exercise to reduce the 
risk of falls and fractures is advised. Cigarette smoking and 
excess alcohol intake (three or more drinks per day) should 
be avoided.
Medications approved for osteoporosis prevention 
include estrogen, raloxifene (an estrogen receptor agonist/
antagonist), and three bisphosphonates, alendronate, rise-
dronate, and ibandronate, all of which are classified as 
antiresorptive (anticatabolic) agents that inhibit osteoclastic 
bone resorption. Those approved for osteoporosis treatment 
include antiresorptive drugs raloxifene, alendronate, risedro-
nate, ibandronate, zoledronic acid, and salmon calcitonin, and 
one anabolic (bone-forming) drug, teriparatide [parathyroid 
hormone (PTH) 1–34].13 Other drugs, such as strontium 
ranelate, etidronate, and PTH (1–84) are approved in some 
countries but not the US.
Registration of a drug for the treatment of osteoporosis in 
the US and the EU requires demonstration of vertebral frac-
ture risk reduction in a phase III randomized, double-blind, 
placebo-controlled clinical trial. Some approved drugs have 
been proven to reduce fractures at other skeletal sites as well. 
For example, there is evidence that alendronate, risedronate, 
and zoledronic acid reduce hip fracture and nonvertebral 
fracture risk,1,15–18 and teriparatide has been shown to reduce 
nonvertebral fracture risk.19 Estrogen has proven fracture 
risk reduction at the spine, hip, and other skeletal sties, but 
is not recommended as first-line therapy for the treatment 
of osteoporosis due to adverse events associated with long-
term use. All of these drugs are approved for the treatment of 
postmenopausal osteoporosis, while alendronate, risedronate, Core Evidence 2009:4 16
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zoledronic acid, and teriparatide are currently approved for 
treatment of osteoporosis in men.
The registration trials for alendronate, risedronate, and 
ibandronate were conducted with daily dosing of medication, 
although the dosing interval most often used now is weekly 
for alendronate, weekly or monthly for risedronate, and 
monthly for oral ibandronate. Ibandronate may also be given 
as an intravenous infusion every three months. Raloxifene, 
nasal calcitonin, teriparatide, and strontium ranelate require 
daily administration. The dosing regimen for oral bisphos-
phonates requires a 30-min postdose fast for alendronate and 
risedronate, and a 60-min postdose fast for ibandronate. Oral 
bisphosphonates have been associated with gastrointestinal 
intolerance in some clinical practice patients, although in 
clinical trials there have been no significant differences in 
gastrointestinal adverse events in bisphosphonate-treated 
patients versus those on placebo. Rarely, bisphosphonates 
have been associated with a syndrome of persistent myalgias 
and arthralgias that may recur on rechallenge.20 Bisphos-
phonates, particularly when given intravenously for cancer 
patients, such as those with multiple myeloma or breast 
carcinoma, have been associated with osteonecrosis of the 
jaw.21 Raloxifene and estrogen share an increased incidence of 
venous thromboembolic events.22,23 Raloxifene is also associ-
ated with an increased incidence of leg cramps and vasomotor 
symptoms24 while estrogen reduces vasomotor symptoms.18 
Teriparatide has been linked with osteosarcoma in rodent 
models.25 Osteosarcoma did not occur when the rodents had 
exposure of less than 70% of their lifespan,26 and does not 
appear to be a problem in adult humans treated with approved 
doses for osteoporosis.27 Teriparatide is also associated with 
transient hypercalcemia 4–6 hours after injection and eleva-
tion of uric acid not associated with clinical gout.19
Unmet needs
Despite the availability of excellent diagnostic tools and 
evidence demonstrating the efficacy of medications to 
treat osteoporosis and reduce fracture risk, a significant 
proportion of patients with osteoporosis is undiagnosed and 
untreated.11,28 Even when patients are treated for osteoporosis, 
it is common for medication to be taken incorrectly or for 
too short a time to provide benefit in terms of fracture risk 
reduction.29
The multinational IMPACT study30 evaluated the accuracy 
of radiographic diagnoses of vertebral fracture in postmeno-
pausal women with a new diagnosis of osteoporosis based on 
BMD measurements. Of 2451 women with evaluable lateral 
spine radiographs, 789 (32%) were found to have at least one 
vertebral fracture, and 266 (34% of those with fractures) were 
not recognized as having a vertebral fracture in reports by 
local radiologists. In a study that analyzed hospital records 
for patients diagnosed with osteoporosis and/or osteoporotic 
fractures, the annual incidence of osteoporosis in women 
50 years or older was estimated to be 58568 per million 
inhabitants; however, only 4823 cases were diagnosed, 
representing just 8.2% of the expected figure.31 In another 
study of 95 patients aged 65 years or older having surgery for 
hip fracture, none had a BMD assessment during hospitaliza-
tion or were scheduled to have it as an outpatient procedure, 
and only 2% reported receiving pharmacologic therapy for 
osteoporosis at discharge.32
Adherence to treatment is less than optimal. Nearly 50% of 
all patients started on weekly alendronate or risedronate remain 
on treatment for less than one year.33 A study of a large US 
pharmacy claims database showed that one-year adherence was 
better with weekly dosing compared with daily (45% compared 
with 33%, respectively), but was still poor.34 Many patients 
express a preference for monthly compared with weekly dosing 
of an oral bisphosphonate.35 Persistence with a monthly drug 
treatment regimen may be better than with weekly, although is 
still suboptimal.36 Poor adherence to therapy is associated with 
adverse clinical outcomes, including greater risk of fractures29 
and higher healthcare costs.36
Clinical evidence with zoledronic acid 
for the treatment of osteoporosis
The key patient-oriented outcome of fractures with zoledronic 
acid therapy for the treatment of osteoporosis has been evalu-
ated in two randomized controlled trials (RCTs): HORIZON-
PFT1 and HORIZON-RFT.2 Both studies assessed the 
disease-oriented outcome of BMD, and HORIZON-PFT, but 
not HORIZON-RFT, measured bone turnover markers.
HORIZON-PFT was a three-year international, multi-
center, randomized, double-blind, placebo-controlled trial 
that enrolled 7765 postmenopausal women (age 65–89 years, 
mean 73 years) with osteoporosis, defined as a BMD T-score 
of -2.5 or less at the femoral neck with or without evidence 
of existing vertebral fracture, or a T-score of -1.5 or less 
with radiologic evidence of at least two mild or one moderate 
vertebral fracture. Previous use of oral bisphosphonates was 
allowed, provided criteria for a predefined washout period 
were met. Concomitant use of the following osteoporosis 
medications was allowed at the time of entry into the study 
and during follow-up: hormone therapy, raloxifene, calci-
tonin, tibolone, tamoxifen, dehydroepiandrosterone, iprifla-
vone, and medroxyprogesterone. Patients were placed into Core Evidence 2009:4 17
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one of two strata according to whether they were taking osteo-
porosis medications at baseline. Those assigned to stratum 1 
were not taking any osteoporosis medications at the time of 
randomization, while those in stratum 2 were all taking an 
allowed medication. Patients with previous bisphosphonate 
treatment who met washout criteria were included in the 
study. Patients were excluded from participation for any pre-
vious use of PTH or sodium fluoride, use of anabolic steroids 
or growth hormone within six months of trial entry, use of oral 
or intravenous systemic corticosteroids within 12 months, and 
any previous use of strontium ranelate. Patients with a serum 
calcium level of more than 11 mg/dL (2.75 mmol/L) or less 
than 8 mg/dL (2 mmol/L), a calculated creatinine clearance 
of less than 30 mL/min at either of two baseline visits, or 
urine dipstick protein of more than 2+ without evidence of 
contamination or bacteriuria were also excluded. Patients 
were randomized to receive a 15-min intravenous infusion 
of zoledronic acid 5 mg (n = 3889) or placebo (n = 3876) at 
baseline, 12 months, and 24 months. A treatment window 
of 90 days (-1 month/+2 months from one-year anniversary 
of prior infusion) was allowed for the administration of 
repeat infusions. All patients received supplemental calcium 
1000–1500 mg and vitamin D 400–1200 IU per day. Primary 
endpoints were new vertebral fractures in stratum 1 and hip 
fracture in both strata. Secondary efficacy endpoints included 
any nonvertebral fracture, any clinical fracture, and clinical 
vertebral fracture. Other secondary endpoints were changes 
in BMD at the total hip, femoral neck, and lumbar spine, and 
changes in bone resorption markers (serum C-telopeptide of 
type I collagen) and bone formation markers (bone-specific 
alkaline phosphatase and N-terminal propeptide of type I 
collagen).
HORIZON-RFT was a randomized, double-blind, 
placebo-controlled trial that enrolled 2127 women and 
men age 50 and older (mean age, 74.5 years) with a recent 
low-trauma hip fracture. All enrolled patients had both legs 
and were walking before the hip fracture. Concomitant 
therapy with nasal calcitonin, selective estrogen receptor 
modulators, hormone replacement, tibolone, and external 
hip protectors was allowed. Prior use of bisphosphonates 
or PTH was allowed according to a prespecified washout 
period. Exclusions included prior use of strontium ranelate 
or sodium fluoride, hypersensitivity to a bisphosphonate, 
potential for pregnancy, calculated creatinine clearance less 
than 30 mL/min, corrected serum calcium level of more than 
11 mg/dL (2.75 mmol/L) or less than 8 mg/dL (2 mmol/L), 
active cancer, metabolic bone disease other than osteoporosis, 
and a life expectancy of less than six months. The duration of 
the study was event driven, with 211 clinical fractures required 
to have a power of 90% to detect a 35% reduction in the rate 
of clinical fracture in the zoledronic acid group compared 
with the placebo group. Patients were assigned to receive a 
yearly 15-min intravenous infusion of zoledronic acid 5 mg 
(n = 1065) or placebo (n = 1062), with the first dose admin-
istered within 90 days after surgical repair of a hip fracture. If 
the baseline serum 25-hydroxyvitamin D level was 15 ng/mL 
or less, or if the level was not available, patients received a 
loading dose of either vitamin D3 or D2 (at 50 000–125 000 IU, 
orally or intramuscularly) 14 days before the first infusion of 
a study drug. Thereafter, all patients received daily supple-
mentation with oral calcium (1000–1500 mg) and vitamin D 
(800–1200 IU). The median follow-up was 1.9 years. The 
primary endpoint was a new clinical fracture, excluding 
fractures of the face and digits, and fractures in abnormal 
bone, such as those seen with metastatic cancer. Secondary 
endpoints included change in BMD in the nonfractured hip, 
new vertebral and nonvertebral fractures, hip fractures, and 
prespecified safety endpoints that included death.
In a one-year study of 225 postmenopausal women with 
low BMD who were previously treated with alendronate for 
at least one year (mean, four years), the safety and efficacy 
of a single intravenous dose of zoledronic acid 5 mg versus 
alendronate 70 mg/week was compared.3 All patients were 
between the ages of 45 and 79 years (mean age, 68 years) 
with a documented T-score less than or equal to -2.0 at the 
lumbar spine or femoral neck prior to initiation of alendronate. 
Patients were excluded for a calculated creatinine clear-
ance less than 30 mL/min, or urine dipstick with more than 
2+ protein without evidence of contamination or bacteriuria; 
serum calcium greater than 11 mg/dL (2.75 mmol/L) or less 
than 8 mg/dL (2 mmol/L); serum alkaline phosphatase more 
than 1.5 times the upper limit of normal; abnormalities of the 
esophagus that may delay esophageal emptying; treatment 
with intravenous bisphosphonates within the last two years; 
treatment with raloxifene, calcitonin, tibolone, or hormone 
replacement therapy within six months prior to randomization; 
and any treatment with strontium ranelate, sodium fluoride, 
or PTH. The primary objective was to evaluate the noninfe-
riority of intravenous zoledronic acid 5 mg compared with 
weekly oral alendronate 70 mg in maintaining BMD at the 
lumbar spine. Secondary objectives included comparison of 
bone turnover markers over 12 months.
Fractures
HORIZON-PFT1 showed that in women with postmeno-
pausal osteoporosis, intravenous infusion of zoledronic acid Core Evidence 2009:4 18
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5 mg every 12 months over three years significantly reduced 
the relative risk of morphometric vertebral fracture compared 
with placebo by 70% [absolute risk reduction (ARR), 7.6%]; 
reduced hip fracture risk by 41% (ARR, 1.1 %); reduced 
clinical vertebral fracture risk by 77% (ARR, 2.1%); reduced 
nonvertebral fracture risk by 25% (ARR, 2.7%); and 
reduced the risk of all clinical fractures by 33% (ARR, 4.4%) 
(Table 2).
In HORIZON-RFT,2 men and women treated with 
intravenous zoledronic acid 5 mg within 90 days of a low-
trauma hip fracture had a significantly reduced risk of clinical 
fracture (35%; ARR, 5.3%), clinical vertebral fracture (46%; 
ARR, 2.1%), and nonvertebral fracture (27%; ARR, 3.1%) 
compared with placebo (Table 3).
BMD
BMD is a surrogate biomarker for bone strength, with 
stability or an increase in BMD associated with a reduction 
in fracture risk in patients treated with effective osteoporosis 
medications.38 In HORIZON-PFT,1 BMD was increased 
significantly at the lumbar spine (6.71%), total hip (6.02%), 
and femoral neck (5.06%) in the zoledronic acid group 
versus the placebo group over three years (P  0.001 for 
all comparisons). In HORIZON-RFT,2 significant BMD 
increases were also observed. BMD at the total hip increased 
by 2.6%, 4.7%, and 5.5% at 12, 24, and 36 months, respec-
tively, over 3 years in the zoledronic acid group, compared 
with decreases of 1%, 0.7%, and 0.9% at the correspond-
ing time points in the placebo group. Femoral neck BMD 
increased in the zoledronic acid group by 0.8%, 2.2%, and 
3.6% at 12, 24, and 36 months, respectively, compared with 
declines of 1.7%, 2.1%, and 0.7% in the placebo group at 
corresponding time points (Figure 1). All increases in total 
hip and femoral neck BMD were statistically significant 
versus placebo (P  0.001).
In postmenopausal women with low BMD who were 
previously treated with alendronate for at least one year,3 there 
was no statistical difference between the BMD response at 
the lumbar spine with a single dose of intravenous zoledronic 
acid 5 mg versus alendronate 70 mg/week, meeting the pre-
defined criteria for noninferiority of zoledronic acid in the 
study population. The observed lumbar spine BMD changes 
were small in both groups, with a change from baseline to 
month 12 of 0.167% (SE, 0.258) in the group receiving zole-
dronic acid 5 mg compared with 0.813% (SE, 0.283) in the 
alendronate 70 mg group in the intent-to-treat population.
Bone turnover markers
Bone turnover markers are biochemical byproducts of bone 
remodeling that can be measured in blood and urine.
Bisphosphonates, including zoledronic acid, exert their 
skeletal effects through inhibition of osteoclastic bone resorp-
tion, which is reflected by a decrease in bone resorption 
markers. Due to coupling of bone resorption and formation, 
bone formation markers typically also decrease, but this 
occurs later than the decrease in bone resorption markers, 
and to a lesser magnitude.
In HORIZON-PFT,1 all three bone turnover markers 
decreased significantly in patients in the zoledronic acid 
group compared with placebo. At 12 months, levels of serum 
C-telopeptide of type I collagen, bone-specific alkaline 
phosphatase, and N-terminal propeptide of type I collagen 
Table 2 relative risk of fracture in postmenopausal women 
with osteoporosis with zoledronic and versus placebo in 
HOriZON-PFT1
Type of  
fracture
Number of patients 
with fractures/total 
number of patients (%)
Relative risk  
or hazard ratio 
(95% CI)
P value 
 
   Placebo  Zoledronic 
acid
     
Morphometric   
vertebral
310/2853 
(10.9%)
92/2822 
(3.3%)
0.30 (0.24–038) 0.001
Hip 88/3861 
(2.5%)
52/3875 
(1.4%)
0.59 (0.42–0.83) 0.002
Clinical  
vertebral
84/3861 
(2.6%)
19/3875 
(0.5%)
0.23 (0.14–0.37) 0.001
Nonvertebral  388/3861 
(10.7%)
292/3875 
(8.0%)
0.75 (0.64–0.87)  0.001 
Abbreviation: CI, confidence interval.
Table 3 relative risk of fracture in men and women with recent 
low-trauma hip fracture with zoledronic acid versus placebo in 
HOriZON-rFT2
Type of  
fracture
No. of patients with  
fractures/total no  
of patients (%)
Hazard  
ratio  
(95% CI)
P value
   Placebo  Zoledronic 
acid
     
All clinical 
fractures
139/1062 
(13.9%)
92/1065 
(8.6%)
0.65 
(0.50–0.84)
0.001
Nonvertebral 107/1062 
(10.7%)
79/1065 
(7.6%)
0.73 
(0.55–0.98)
0.03
Hip 33/1062 
(3.5%)
23/1065 
(2.0%)
0.70 
(0.41–1.19)
0.18
Clinical 
vertebral
39/1062 
(3.8%)
21/1065 
(1.7%)
0.54 
(0.32–0.92)
0.02 
Abbreviation: CI, confidence interval.Core Evidence 2009:4 19
Zoledronic acid Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
were 59% (95% confidence interval [CI]: 55, 63), 30% (95% 
CI: 27, 32), and 58% (95% CI: 55, 60) lower, respectively, in 
the zoledronic acid group (P  0.001 for all) compared with 
placebo. At 6 and 12 months after each of the three infusions, 
the mean values were similar, with no progressive decline 
in bone marker levels.
In postmenopausal women with low BMD who were 
previously treated with alendronate,3 a single dose of intra-
venous zoledronic acid 5 mg significantly decreased bone 
turnover markers at three months compared with baseline, 
with a subsequent rise in levels to greater than baseline, yet 
well within the premenopausal reference range, at nine and 
12 months. The decrease in bone turnover marker levels at 
three months with zoledronic acid suggests that alendronate 
does not maximally suppress bone turnover, and the subse-
quent rise in levels appears to represent reversibility of the 
potent antiresorptive effect of zoledronic acid.
Safety and tolerability
Once yearly intravenous infusion of zoledronic acid 5 mg 
for the treatment of osteoporosis is associated with a favor-
able safety profile and is generally well tolerated. Key safety 
issues are discussed below.
Acute phase (postdose) reaction
The five most common postdose symptoms (within three days 
of infusion) reported in HORIZON-PFT1 were pyrexia 
(16.1 % versus 2.1 % with placebo), myalgia (9.5% versus 
1.7%), influenza-like symptoms (7.8% versus 1.6%), headache 
(7.1 % versus 2.3%), and arthralgia (6.3% versus 2.0%) 
(P  0.001 for all comparisons). These symptoms typically 
resolved within three days of onset and declined markedly after 
the first infusion. Any of these postdose symptoms occurred 
in 31.6% of patients receiving zoledronic acid after the first 
infusion, 6.6% after the second infusion, and 2.8% after 
the third infusion. Administration of antipyretics (eg, acet-
aminophen, ibuprofen) seemed to mitigate these symptoms. 
In HORIZON-RFT,2 fewer acute phase reactions were seen, 
possibly due to the routine use of acetaminophen for up to 
72 hours following the infusion.
Previous treatment with a bisphosphonate appears to 
provide some protection from acute phase reactions with zole-
dronic acid.3 Similar postdose symptoms have been observed 
with other bisphosphonates, administered intravenously and 
orally, and appear to be due, at least in part, to the release of 
inflammatory cytokines from circulating T cells.39
Osteonecrosis of the jaw
Osteonecrosis of the jaw (ONJ) is a rare disorder of the 
oral cavity that has recently been defined as the presence 
of exposed bone in the maxillofacial region that does not 
heal within eight weeks after identification by a healthcare 
provider.21 Most cases of bisphosphonate-related ONJ (about 
94%) have been reported in patients who receive monthly 
intravenous bisphosphonates for the treatment of malignan-
cies, particularly multiple myeloma and metastatic cancer.40 
Potential risk factors for ONJ include long duration of 
exposure to bisphosphonate treatment, glucocorticoid use, 
recent dental extraction, invasive oral bone surgery, poorly 
fitting dental appliances and/or intraoral trauma, preexisting 
dental or periodontal disease, cancer, anticancer therapy, and 
alcohol/ tobacco abuse.21
In HORIZON-PFTand HORIZON-RFT there were no 
spontaneous reports of ONJ.1,2 To identify potential unre-
ported cases among HORIZON-PFT patients, the adverse 
event database was searched using 60 safety terms chosen by 
a panel of maxillofacial experts. An independent adjudication 
committee that was blinded to study treatment then reviewed 
all identified events. Possible ONJ cases were defined as 
exposed bone in the maxillofacial area with delayed healing 
of more than six weeks despite appropriate care. Two poten-
tial cases of ONJ were identified in HORIZON-PFT, one 
in the placebo group and one in the zoledronic acid group, 
with each of these resolving with antibiotic treatment and 
debridement.
Figure 1 Change in BMD during 3 years’ treatment with yearly zoledronic acid 5 mg 
(n = 1065) or placebo (n = 1062) in patients aged 50 years (mean age, 74.5 years) 
with a recent low-trauma hip fracture (HOriZON-rFT)2 P  0.001 zoledronic acid 
vs placebo at all time points. 
Abbreviation: BMD, bone mineral density.
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These findings are consistent with previous reports 
suggesting that the risk of ONJ in bisphosphonate-treated 
osteoporosis patients is low (an estimated prevalence of less 
than one in 100 000 patient years in noncancer patients), 
and that the benefit of bisphosphonate therapy in prevent-
ing fractures generally far outweighs the risk of ONJ.21 
A review of the adjudicated cases of ONJ in HORIZON-PFT 
concluded that there is no evidence to suggest that healthy 
patients receiving bisphosphonates for osteoporosis require 
any special dental treatment beyond routine care and standard 
procedures.41 It is probably prudent for clinicians to do a 
routine oral examination before prescribing a bisphosphonate 
and to consider appropriate preventive dental care prior to 
treatment in patients with a history of ONJ risk factors.
renal effects
Intravenous bisphosphonates have been associated with 
adverse renal effects that are primarily related to dose and infu-
sion time, with the risk increasing with higher dose and faster 
infusion time.42 In HORIZON-PFT and HORIZON-RFT, 
using zoledronic acid 5 mg with an infusion time of 15 min, no 
long-term effects on renal function were observed. In HORI-
ZON-PFT,1 there was a transient increase in serum creatinine 
(defined as a rise of more than 0.5 mg/dL) in 1.2% of zole-
dronic acid patients compared with 0.4% of placebo patients 
(P  0.001). Within 30 days after infusion, the levels returned 
to within 0.5 mg/dL of preinfusion values in over 85% of 
patients, with the remainder of patients back to this level by 
the time of the next annual follow up. In HORIZON-RFT,2 
the incidence of serum creatinine elevations 0.5 mg/dL did 
not differ between the zoledronic acid and placebo groups 
(6.2% and 5.6%, respectively, P = not significant).
Hypocalcemia
In HORIZON-PFT, at nine to 11 days after the first infusion, 
0.2% of patients in the zoledronic acid group had a decrease 
in serum calcium level to less than 7.5 mg/dL1 as did 0.3% of 
those in HORIZON-RFT zoledronic acid group.2 All events 
were transient and asymptomatic.
Ocular events
In HORIZON-PFT, patients treated with zoledronic acid had 
an absolute increase of approximately 0.69% (3.34% with 
zoledronic acid versus 2.65% with placebo) in inflammatory 
ocular adverse events, primarily conjunctivitis, during the first 
15 days after infusion.1 In HORIZON-RFT, four patients in the 
zoledronic acid group (0.4%) and one patient in the placebo 
group had an ocular event that was considered possibly or prob-
ably related to study drug according to an expert review.2
Cardiovascular events
In HORIZON-PFT, there were more cardiac rhythm 
disturbances in the group receiving zoledronic acid 
(266 patients, or 6.9%) than placebo (203 patients, or 5.3%, 
P = 0.003) and serious atrial fibrillation, a subcategory of all 
arrhythmias, was more common with patients in the zole-
dronic acid group.1 A total of 50 patients in the zoledronic 
acid group had serious atrial fibrillation (1.3%) compared 
with 20 patients (0.5%) in the placebo group (P  0.001). 
After adjudication, the number of patients whose atrial 
fibrillation was reported as a serious adverse event remained 
similar (50 in the zoledronic acid group and 17 in the placebo 
group). In most zoledronic acid recipients with atrial fibril-
lation (47/50), the event occurred more than 30 days after 
infusion. In a preplanned substudy of 559 patients who under-
went electrocardiography, the prevalence of atrial fibrillation 
(2.1% in the zoledronic acid group and 2.8% in the placebo 
group) and other electrocardiographic abnormalities was not 
significantly different between the study groups. There was 
no significant difference in incidence of atrial fibrillation 
overall, and no difference in strokes, deaths due to strokes, 
myocardial infarction, or death from cardiovascular diseases. 
In HORIZON-RFT,2 there was no significant difference in 
cardiovascular events in the two groups and no difference 
in atrial fibrillation as a serious adverse event.
The clinical significance, if any, of the finding of 
increased risk of serious atrial fibrillation in patients treated 
with zoledronic acid in HORIZON-PFT is unclear. Cardiac 
arrhythmias have not been reported in other RCTs of patients 
treated with bisphosphonates, and retrospective studies have 
shown conflicting results, with some suggesting an increased 
risk43 and others suggesting no increase in risk.44
Mortality
Patients treated with zoledronic acid in HORIZON-RFT had 
a 28% lower risk of all-cause mortality than those receiving 
placebo (9.6% versus 13.3%, P = 0.01).2 Factors responsible 
for the mortality reduction are not clear. The adjudication 
committee determined that in the zoledronic acid group 
11 deaths (1.0%) were from cardiovascular disease and seven 
(0.7%) were from cerebrovascular disease; in the placebo 
group, there were 18 deaths (1.7%) from cardiovascular 
disease and seven (0.7%) from cerebrovascular disease. 
While osteoporotic fractures of the hip and spine are 
associated with increased mortality,44 and it seems intuitive 
that reduction in fracture risk would reduce mortality, this 
is the first time that a mortality benefit has been reported in 
a RCT with a drug for the treatment of osteoporosis.Core Evidence 2009:4 21
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Economic evidence
The cost of zoledronic acid once yearly for the treatment of 
osteoporosis is similar to the annualized cost for monthly 
oral risedronate and ibandronate; as a result, it is expected 
to demonstrate comparable cost-effectiveness. Alendronate 
is the only generic bisphosphonate currently available. The 
WHO recently released a clinical tool for estimation of the 
10-year probability of fracture, FRAX™.8 This can be used 
in combination with country-specific data such as fracture 
rates, healthcare costs associated with fractures, and societal 
willingness to pay, to develop cost-effective intervention 
thresholds for pharmacologic therapy. The NOF has evalu-
ated the WHO methodology and determined that it can be 
adapted for use in the US,46 and a cost-effectiveness analysis 
identified 10-year fracture probabilities at which it is cost-
effective to treat.47 The latter used a Markov cohort model 
of annual US age-specific incidence of clinical hip, spine, 
forearm, shoulder, rib, pelvis, and lower leg fracture, costs 
in 2005 $US, and quality-adjusted life years (QALYs) to 
assess the cost-effectiveness of osteoporosis treatment, 
assuming $US600/year drug cost for five years with a 35% 
reduction in fracture risk and acceptable cost to society of 
up to $US60 000 per QALY gained. The conclusion was 
that it is cost-effective to treat when the 10-year probability 
of hip fracture using the WHO algorithm is approximately 
3% or more.
The updated NOF guide for the prevention and treatment 
of osteoporosis13 considered cost-effectiveness in establish-
ing its recommendations to treat postmenopausal women 
and men aged 50 years and older under the following 
circumstances: a hip or vertebral (clinical or morphometric) 
fracture; T-score -2.5 or below at the femoral neck, total hip 
or spine after appropriate evaluation to exclude secondary 
causes; low bone mass (T-score between -1.0 and -2.5 at the 
femoral neck, total hip, or spine) and 10-year probability of 
hip fracture 3% or greater or a 10-year probability of major 
osteoporosis-related fracture 20% or greater based on the 
US-adapted WHO algorithm. The NOF lists zoledronic acid 
as an FDA-approved drug for the treatment of osteoporosis 
but does not categorize the cost-effectiveness of individual 
drugs and recognizes that clinical decisions on whom to 
treat and how to treat must consider factors in addition to 
cost-effectiveness.
Resource utilization
The US Surgeon General11 and the NOF13 have described 
osteoporosis as a public health problem of huge magnitude, 
with clinical consequences and healthcare costs that are 
expected to increase with the aging of the population. This 
is likely to extract a large toll in terms of personal suffer-
ing, lost productivity for the patient and family caregivers, 
and higher healthcare costs for individuals and society. The 
morbidity of osteoporotic fractures, especially those of the 
hip and spine, are a strain on interpersonal relationships 
between patients and their families. Osteoporosis-related 
fractures create a heavy economic burden, causing over 
432 000 hospital admissions, almost 2.5 million medical 
office visits, and about 180 000 nursing home admissions 
annually in the US.11 The cost to the healthcare system associ-
ated with osteoporosis-related fractures has been estimated 
at $US17 billion in 2005; hip fractures account for 14% of 
incident fractures and 72% of fracture costs.9 Due to the aging 
population, the Surgeon General estimates that the number 
of hip fractures and their associated costs could double or 
triple by the year 2040.
The use of intravenous zoledronic acid 5 mg every 
12 months in appropriately selected patients can be expected 
to substantially reduce the risk of fractures. This in turn 
will result in fewer fracture-related hospitalizations, office 
visits, and nursing home admissions, as well as a reduction 
in fracture-related healthcare expenses.
Patient group/population
RCTs have shown fracture risk reduction with annual 
intravenous zoledronic acid 5 mg in women with postmeno-
pausal osteoporosis and in men and women with recent 
low-trauma hip fracture. The safety and tolerability profile 
has been generally very good. These groups can expect 
to benefit from fracture risk reduction with greater conve-
nience and perhaps improved adherence compared with the 
more frequent oral dosing of other medications with proven 
fracture risk reduction. Zoledronic acid is an attractive option 
for women with postmenopausal osteoporosis because of 
the assured 12-month compliance, but can also be used in 
women who are not able to take oral bisphosphonates due to 
gastrointestinal intolerance, gastrointestinal contraindication, 
or malabsorption.
Dosage, administration, 
and formulations
Zoledronic acid is an injectable aminobisphosphonate with 
potent antiresorptive activity and high affinity for mineral-
izing bone. It is administered as a 5 mg intravenous infusion 
through vented intravenous tubing over no less than 15 min. 
It is supplied in a prepackaged bottle of zoledronic acid 
5 mg/100 mL. After opening the solution, it is stable for Core Evidence 2009:4 22
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24 hours at 2–8 °C (36–46 °F). If refrigerated, the refrigerated 
solution should be allowed to reach room temperature before 
administration. Storage is recommended at 25 °C (77 °F) with 
excursions permitted to 15–30 °C (59–86 °F).
Patients, especially those on diuretic therapy, should be 
hydrated prior to administration of zoledronic acid; drinking 
several glasses of water before leaving home is probably 
sufficient for most patients. Zoledronic acid should be used 
with caution in patients taking other drugs that are potentially 
nephrotoxic. Since transient increases in serum creatinine 
may be greater in patients with impaired renal function, zole-
dronic acid is not recommended in patients with creatinine 
clearance less than 35 mL/min.
To reduce the risk of hypocalcemia and for general bone 
health, patients should have an adequate intake of calcium 
and vitamin D. The NOF recommends a daily intake of at 
least 1200 mg elemental calcium with diet plus supplements, 
if needed, and vitamin D3 800–1000 IU/day.
Clinical value
Osteoporosis is a major public health problem associated with 
significant morbidity and mortality, resulting in a substantial 
personal burden to patients and caregivers, and an economic 
burden to individuals and a healthcare system with limited 
resources. It is underdiagnosed and undertreated, and when 
treated, many patients do not take medication correctly or 
do not take it long enough to achieve the expected benefit. 
Efforts to optimize skeletal health in all patients include 
regular physical activity, adequate intake of calcium and 
vitamin D, and avoidance of cigarette smoking and excess 
alcohol. When drug therapy to reduce fracture risk is started, 
it is imperative that patients take medication regularly, cor-
rectly, and long enough to benefit from the reduction in 
fracture risk.
The use of once yearly intravenous zoledronic acid 
offers the potential to improve effectiveness in clinical 
practice by providing 100% bioavailability, eliminating 
concern of malabsorption of oral bisphosphonates due to 
intestinal disease or incorrect administration, and provid-
ing a drug that reduces bone turnover for at least one year 
after a single infusion. It has proven antifracture efficacy at 
all important skeletal sites in women with postmenopausal 
osteoporosis, and has been shown to reduce the risk of new 
clinical fractures, as well as all-cause mortality, in men and 
women with a previous hip fracture. It is associated with 
a favorable safety profile and was generally well tolerated 
in both large fracture prevention trials. Postdose, flu-like 
symptoms in clinical trials were transient, and in clinical 
practice such symptoms may be mitigated by treatment 
with acetaminophen or ibuprofen. Intravenous zoledronic 
acid is especially attractive for patients with gastrointestinal 
contraindications to oral bisphosphonates, gastrointestinal 
intolerance to oral bisphosphonates, or malabsorption of oral 
bisphosphonates.
In conclusion, zoledronic acid is an important new thera-
peutic option in the management of patients with osteopo-
rosis, potentially leading to improved clinical outcomes and 
reducing the burden of osteoporotic fractures.
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